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Running Head: Monitoring Matrix-Induced Autophagy

Summary
A growing body of research demonstrates modulation of autophagy by a variety of matrix constituents,
including decorin, endorepellin, and endostatin. These matrix proteins are both pro-autophagic and
anti-angiogenic. Here, we detail a series of methods to monitor matrix-induced autophagy and its
concurrent effects on angiogenesis. We first discuss cloning and purifying proteoglycan fragment and
core proteins in the laboratory and review relevant techniques spanning from cell culture to treatment
with these purified proteoglycans in vitro and ex vivo. Further, we cover protocols in monitoring
autophagic progression via morphological and microscopic characterization, biochemical western blot
analysis, and signaling pathway investigation. Downstream angiogenic effects using in vivo approaches
are then discussed using wild-type mice and the GFP-LC3 transgenic mouse model. Finally, we explore
matrix-induced mitophagy via monitoring changes in mitochondrial DNA and permeability.
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1. Introduction
A vast and complex reservoir, the extracellular matrix (ECM) contributes an abundance of dynamic
roles to surrounding cells to maintain tissue homeostasis and sustain development (1-16). A major
constituent of the ECM, proteoglycans fulfill a range of structural and signaling roles that regulate
cellular processes including endocytosis (17-20), cell adhesion (21-24), inflammation and wound
healing (25,26), thrombosis (27), angiogenesis (28-31), and autophagy (32-34). Autophagy is the “selfeating”

process

by

which

cells

deliver

intracellular

proteins,

lipids

and

organelles

to

lysosomal compartments for degradation and recycling. Independent of nutrient deprivation, several
matrix constituents effectively modulate this intracellular degradative pathway, among which are
decorin, endorepellin, endostatin, and kringle V (35).
Decorin, a small leucine-rich proteoglycan (SLRP), functions as a pan-receptor tyrosine kinase inhibitor
and impedes endothelial cell migration while activating autophagy (32,36,37). Similarly, endostatin, is
the 20-kDa C terminal fragment of collagen XVIII-1, exerts its angiostatic activity by binding to 51
integrin and inducing autophagy through Vps34, Beclin 1, and LC3-II (38,39). Kringle V, instead, is an
internal proteolytic fragment of plasminogen that induces autophagy in endothelial cells via binding to
glucose-regulated protein 78 kDa (GRP78) while exhibiting potent anti-angiogenic effects on
endothelial cell migration and proliferation (40).
Endorepellin is the proteolytically processed C terminal fragment of the substantial heparan sulfate
proteoglycan perlecan (41,42) a proteoglycan with a complex biology (43-48)involved in the regulation
of angiogenesis, both developmental and experimental

(28,49-52). Located in the basement

membrane of vascular endothelial cells, endorepellin has recently emerged as a soluble pro-autophagic
and anti- angiogenic molecule of the ECM, inhibiting endothelial cell migration, capillary
morphogenesis, and proliferation (53-59). Through its three laminin-like globular (LG) domains and
partial agonistic activity, it signals dually through vascular endothelial growth factor receptor 2
(VEGFR2) to induce protracted autophagy and the α2β1 integrin for actin cytoskeleton dissolution,
leading to an anti-migratory and angiostatic phenotype (55,60-63). Downstream of endorepellin
signaling through VEGFR2, 5’–adenosine monophosphate-activated protein kinase (AMPK) is
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phosphorylated at Thr172, leading to inhibition of mammalian target of rapamycin (mTOR) and
induction of autophagy markers including paternally-expressed gene 3 (Peg3), Beclin 1, LC3-II, and
p62 (32,33,64,65) (Fig. 1). These effects mirror that of Torin 1, a selective competitive inhibitor of
mTOR (66).
Ultimately, these ECM molecules interact with their respective receptors to elicit downstream signaling
pathways that converge on activating players in the core autophagic machinery including Vps34, Beclin
1, and LC3 (32,33,64,65,67). They represent a persistent, robust link between autophagy induction and
angiogenic inhibition controlled by the extracellular microenvironment. A comprehensive study of these
matrix proteins requires experimental treatment ranging from in vitro to in vivo models. The most
powerful and effective tool for this is to clone and purify these matrix proteins in the laboratory, ensuring
the user’s control over the integrity, purity and quality of the protein.
The ability of certain matrix proteins to induce autophagy while inhibiting vascular growth has shown
undeniable clinical promise in the identification of therapeutic targets. In the context of tumorigenesis,
stimulating autophagy has been shown to be beneficial for preventing cancer development as it limits
inflammation, tissue damage, and genome instability (68). These pro-autophagic matrix proteins are
showing angiostatic effects in numerous cancer models, including cancer of the lung, breast,
esophageal, and prostate (57,69,70,70-73). This complex interplay between tumor cells and their
vascularized stroma has profound effects on cancer growth regulation (3,74-79) as angiogenic vessels
exert paracrine and angiocrine modes of regulation (80). Here, we measure the effects of matrixmodulated angiogenesis through an ex-vivo aortic ring assay. In this assay, the outgrowth of newly
formed blood vessels from the mouse thoracic aorta is indicative of a successful angiogenic process.
The growing vessels recruit smooth muscle cells and pericytes to associate with the endothelial cell
tube, de facto recapitulating the anatomy of mature blood vessels in vivo. Furthermore,
autophagosomes can be directly observed in transgenic GFP-LC3 mice after autophagy stimulation
through starvation. Protocols concerning tissue extraction for biochemical western blot analysis and
mouse organ dissection for immunohistochemistry are also comprehensively detailed here.
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To visualize autophagosomes, electron microscopy remains the best method to clearly depict the
double-membrane structure of these vesicles because it allows to precisely distinguish ultrastructures
belonging to lysosomes and other vacuoles in the cell. Over the last half-century, scientists have
generated novel techniques such as confocal fluorescence microscopy and atomic force microscopy to
study the autophagosomes. Immunofluorescence especially comes in handy to analyze different steps
of autophagy in which autophagosomal marker proteins such as microtubule-associated light chain β
(LC3β) and sequestosome-1 (p62/SQSTM1) are stained or tagged with fluorophores (81).The levels of
expression of these proteins are also detectable by western blotting for further confirmation.
Although morphological analysis of autophagosomes via microscopic techniques was the key first step
towards the discovery of the phenomenon of autophagy, it was not sufficient to study the functional
aspect of the autophagy. In order to identify proteins as autophagic substrates, autophagosomelysosome fusion is often inhibited via Bafilomycin A1 or chloroquine. This impedes degradation of
proteins undergoing autophagy and causes a build-up of autophagosomes, both of which can be
detected by western blotting or immunofluorescence (82). Ultimately, this measures autophagic flux,
the measure of autophagic degradation activity, and is an effective method to study proteolytic
processing of various proteins of interest.
Organelle-specific autophagy utilizes distinct molecular pathways for autophagic degradation of the
target. As such, unique proteins and factors are often involved for detecting the type of “-phagy” being
examined (83). In the final section, we will discuss established methods for evaluating mitophagy
(mitochondrial autophagy) (84) that occurs downstream of decorin and endorepellin signaling. Mounting
evidence (85) indicates mitochondrial turnover via specific autophagic processes is a paramount
mechanism for mitochondrial quality control and overall cellular homeostasis.
Determining the extent of mitochondrial degradation proceeds through two primary means: imaging and
biochemistry. Quantitation of mitochondrial specific chaperones residing within the mitochondrial matrix
such as Hsp10, Hsp60, Hsp70; proteases such as Lon and AAA proteinases; and outer mitochondrial
membrane proteins such as PTEN-induced putative kinase 1 (PINK1), adenine nucleotide translocator
(ANT), and voltage-independent anion channel (VDAC1) via immunoblotting and mitochondrial DNA
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(mtDNA) via qPCR are absolutely essential. Complementing mtDNA analysis is mitochondrial
transcription factor A (TFAM) detection via immunoblotting as TFAM coats the mtDNA and is the sole
component found in every mtDNA nucleoid (86,87). Examining oxidative phosphorylation subunits via
immunoblot further reinforce accelerated mitochondrial turnover following stimulation by decorin or
endorepellin. Collectively, data gleaned from both mtDNA clearance and matrix or inner mitochondrial
membrane proteins are considered as strict criteria for mitophagy.
Determining the mitochondrial membrane potential gives a clear assessment of the mitochondrial
permeability pore and its sensitivity to increased Ca2+ uptake. Mitochondrial dyes such as JC-1 are
useful for measuring this property and is often a harbinger of a future mitophagic processes. There is
no one singular empirical scientific methods or assays to determine, conclusively, the initiation and
progression of mitophagy in mammalian cells. However, using a combination of methods, as outlined
below, will give a support for this dynamic process. Therefore, we will discuss the quantification of the
mtDNA and mitochondrial membrane potential determination via JC-1 staining.

2. Materials
2.1. Cloning of Recombinant Proteoglycans and Purification of His-tagged Recombinant
Proteoglycans
1. Veriti 96 well thermal cycler.
2. Lysogeny broth (LB) media and LB agar plates (±100 g/ml ampicillin). Prepare 250 ml of LB
media dissolving 6.25 g of LB broth powder in 250 ml water. Prepare 500 ml LB Agar dissolving
20 g of LB broth with agar powder in 500 ml water). Autoclave liquids. Make 100 mg/ml
Ampicillin stock: 0.15 g in 1.5 ml water, filter sterilized in epitube, and store at -20°C. Cool LB
broth media and LB Agar and add Ampicillin (100 g/ml). Pour Agar in 10 cm plates in the
presence of a Bunsen burner (~18 ml/plate). Cool and store labeled plates at 4°C upside down
to prevent condensation on agar.
3. Competent Escherichia coli cells.
4. Incubating orbital shaker.
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5. Glycerol stock (50% glycerol, 50% water).
6. QIAprep Spin Miniprep Kit.
7. GeneJET gel extraction kit.
8. CutSmart buffer, Ligase buffer, T4 DNA Ligase, NheI and PmeI restriction enzymes.
9. 50X Tris-acetate-EDTA (TAE) buffer (pH 8.5): 242 g Tris base, 57.1 ml acetic acid, 100 ml 0.5
M EDTA; adjust pH to 8.5 and add water up to 1 L.
10. Agarose gel (1%). Microwave 1 or 2 g agarose in 100 ml 1X TAE (2 ml 50X TAE, 98 ml water)
for 1 min for 1% and 2% gel, respectively. Wait 3 min to cool. Add 3 l Ethidium Bromide. Pour
liquid into gel mold.
11. Nanodrop 2000.
12. Short blades.
13. Human embryonic kidney cells expressing the Epstein-Barr virus nuclear antigen (HEK 293EBNA cells).
14. OptiMEM (reduced serum with HEPES and sodium bicarbonate).
15. Lipofectamine 2000.
16. Supplemented Dulbecco’s Eagle Modified Medium (DMEM): 4.5 g/L glucose, L-glutamine, and
sodium

pyruvate,

10%

Fetal

Bovine

Serum

(heat

inactivated

and

filtered),

1%

Penicillin/Streptomycin, 225 g/ml G418 sulfate (with or without 2 g/ml puromycin)
17. Hank’s Balanced Salt Solution (HBSS).
18. EDTA-free proteinase inhibitor mini tablet.
19. Dialysis membrane (MWCO 6-8 kDa, Spectra/Por).
20. PEG 3350/Carbowax.
21. HisPur Ni-NTA resin beads.
22. 1X Equilibration Buffer: 20 mM Na3PO4, 300 mM NaCl, and 10 mM Imidazole all dissolved in
phosphate buffer saline (PBS), pH 7.4.
23. 1X Binding Buffer: 25 mM Imidazole in PBS, pH 7.4.
24. 1X Elution Buffer: 250 mM Imidazole in PBS, pH 7.4.
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25. 10% polyacrylamide gel: 4.796 ml water, 2.5 ml acrylamide (39:1 acrylamide/bisacrylamide,
40% solution), 2.5 ml 1.5 M Tris-HCl (pH 8.8), 0.1 ml 10% sodium dodecyl sulfate (SDS), 0.1 ml
10% ammonium persulfate (APS), 4 l Tetramethylethylenediamine (TEMED).
26. Coomassie Brilliant Blue Dye: 450 ml methanol, 100 ml acetic acid, 450 ml distilled water, 3 g
Coomassie Brilliant Blue R250; filtered.
27. Destain solution: 45% methanol, 10% acetic acid in distilled water.
2.2. Endothelial Cell Culture, Proteoglycan treatment, and Preparation of Lysate
1. Attachment factor (0.2% gelatin in PBS)
2. 12-well cell culture plates.
3. VascuLife EnGS Endothelial Medium (Lifeline Cell Technology) (see Note 1).
4. Human Umbilical Vein Endothelial Cells (HUVEC).
5. Sterile 15 ml tubes.
6. Purified recombinant proteoglycan (see Purification of His-tagged Recombinant Proteoglycan
methods).
7. Sterile PBS.
8. Radioimmunoprecipitation assay (RIPA) buffer: 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM
EGTA, 1 mM EDTA, 1% Triton-X 100, 0.5% sodium deoxycholate, 0.5% SDS, 1 mM Sodium
orthovanadate, 1 EDTA-free protease inhibitor tablet, 1 µg/ml leupeptin, 1 µg/ml aprotinin, 100
µM TPCK, 1 mM PMSF.
9. Cell scraper.
10. 5X Sample buffer: 25 ml 1.25 M Tris-HCl (pH 6.8), 50 ml glycerol, 10 g SDS, 4 ml 0.6%
bromophenol blue.
2.3. Biochemical Analysis of Autophagic Flux and Cell Signaling
1. Antibodies (Table 2).
2. Tris buffered saline (TBS) 10X: for 1L of solution, 30 g of Tris base, 80 g of sodium chloride
(NaCl), 2 g potassium chloride (KCl) were dissolved in 800 ml water, stirred until the
components entered the solution and the final volume was made up to 1 L.
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3. Tris buffered saline tween (TBST) 1X: 100 ml of 10X TBS, 1 ml of Tween20 was dissolved in
900 ml of sterile water.
4. Blocking Buffer: 1% bovine serum albumin (BSA) (w/v) in TBST, store at room temperature.
5. Chemiluminescent substrate: SuperSignalTM west dura extended duration pico kit.
6. Transfer cassette unit: mini trans-blot cell.
7. Visualizing western blots – Image Quant LAS 4000.
8. Torin 1.
9. Chloroquine.
10. Bafilomycin A1.
11. Compound C.
12. SU5416.
2.4. Microscopic Visualization of Autophagy
2.4.1. Electron microscopy
1. Glutaraldehyde 2% (v/v).
2. Osmium tetraoxide 1% (v/v).
3. Graded ethanol (40%, 50%, 60%, 70%, 90%, 96% and 100%).
4. Embedding medium Spurr’s resin (Spurr’s solution: 33% resin, 66% resin and 100% resin).
5. UC7 Ultramicrotome with glass knives and diamond knives (Leica).
6. Toluidine Blue O stain.
7. Light microscope.
8. Copper grids.
9. Uranyl acetate (1-5% solution in water).
10. Lead citrate (0.2% of lead citrate in 0.1N sodium hydroxide).
11. JEOL 100 CX II electron microscope with Advantage HR digital CCD Camera System.
2.4.2. Atomic Force Microscopy (AFM)
1. Dimension icon AFM
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2. Glutaraldehyde 2% (v/v) in HBSS: for 10 ml solution 0.2 ml of glutaraldehyde was dissolved in
10 ml HBSS (freshly prepared solution).
3. Desiccation chamber.
2.4.3. Immunofluorescence Microscopy
1. 4-chamber slides (Nunc™ Lab-Tek™ II CC2™ chamber slide system)
2. Glass cover slips (24 X 60 mm)
3. Fixative solution [4% paraformaldehyde (PFA) in PBS]: for 500 ml solution, 20 g of PFA powder
was added to 400 ml of warm 1X PBS solution followed by dropwise addition of 1N NaOH
solution to allow dissolution of PFA, adjust the volume of the solution to 500 ml with 1X PBS and
the pH was rechecked and set to 6.9 with small amounts of hydrochloric acid, working fraction
of the solution was stored at 4°C for a month and rest of the solution was aliquoted and frozen
at (-20°C) for long term storage (see Note 2).
4. Permeabilization agent: 0.01% Tween20, 1% BSA in PBS (see Note 3).
5. Blocking agent: 1% BSA in PBS (see Note 4).
6. Primaries antibodies (Table 1).
7. Hard set mounting medium with DAPI (Vectashield).
8. Confocal microscope: Zeiss LSM780 NLO confocal/multiphoton microscope.
9. Fluorescence microscope: Leica upright fluorescence microscope DM5500B.
2.5. Monitoring autophagy and angiogenesis ex vivo
Aortic ring assay
1. 3D collagen: collagen type I rat tail (4.5 mg/ml), 199 media 10X (phenol red free), sterile water,
sterile sodium bicarbonate, sterile 1M sodium hydroxide (see Note 5-6).
2. 50 ml syringes.
3. 0.22 µm filters.
4. Wild-type C57BL/6 mice.
5. Hank’s balanced salt solution (HBSS).
6. 96-well plates.

10

7. 70% (v/v) ethanol to surface sterilize the mouse body.
8. Scalpel, sharp scissors, dissection forceps, blade, T-pins, paper towels.
9. Biohazard bag.
10. VascuLife EnGS Endothelial Medium.
11. Blocking Buffer: 2% BSA in PBS.
12. 4% PFA in PBS.
13. Lectin-1-TRITC.
14. Confocal microscope: Zeiss LSM780 NLO confocal/multiphoton microscope.
15. DAPI diluted 1:1000 in PBS.
2.7. Detecting autophagy and angiogenesis in vivo
2.7.1. Starvation-Induced Autophagy in GFP-LC3 Mouse Models
1. GFP-LC3 transgenic mice (Riken).
2. 500 ml 4% PFA in PBS filtered.
3. 1X PBS.
4. 500 ml 15% sucrose in PBS, made fresh each time.
5. 500 ml 30% sucrose in PBS, made fresh each time.
6. Scalpels (1 per mouse group).
7. CO2 chamber and extra cage.
8. Liquid nitrogen in metal bucket.
9. 50 ml tubes (1 per mouse) filled with ~40 ml 4% PFA in PBS filtered.
10. Flat Styrofoam surface for dissection.
11. 28.5 gauge needles (1 per mouse).
12. Labeled 1.5 ml tubes (labeled with mouse and organ).
13. 1 tweezer.
14. 1 dissection scissor.
15. 0.5 M EDTA.
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2.7.2. Mouse Tissue Extraction for Western Blot
1. Mortar and pestle.
2. Labeled pairs of tubes for each tissue sample.
3. Liquid Nitrogen in metal bucket.
4. Tissue extraction solution: In 49 ml T-PER (Tissue protein extraction reagent, Thermo Fisher)
add 500 l Halt Protease Inhibitor (100X) and 500 l 0.5 M EDTA.
5. Nanodrop 2000.
6. 5X Sample Buffer: 25 ml 1.25 M Tris-HCl (pH 6.8), 50 ml glycerol, 10 g SDS, 4 ml 0.6%
bromophenol blue.
7. 10% acrylamide gel: 4.796 ml water, 2.5 ml acrylamide (39:1 acrylamide/bisacrylamide, 40%
solution), 2.5 ml 1.5 M Tris-HCl (pH 8.8), 0.1 ml 10% SDS, 0.1 ml 10% APS, 4 l TEMED.
8. Microcentrifuge.

2.7.3. Immunohistochemistry of Tissue Angiogenic Markers
1. Optimal cutting temperature (OCT) compound.
2. Tissue mounts (Biopsy Cassettes).
3. Colorfrost Plus Microscope Slides.
4. Glass cover slips.
5. Dry ice.
6. Cryostat machine.
7. Desiccator and vacuum attachment.
8. Blocking solution: 5% BSA in PBS.
9. 1X PBS.
10. Vertical glass slide container.
11. Hard set mounting medium with DAPI (Vectashield).

2.8. Monitoring Mitophagy
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2.8.1. Mitochondrial DNA determination
1. RNAzol B.
2. Extraction Buffer (EB): 4 M guanidine thiocyanate, 50 mM sodium citrate, and 1 M Tris-free
base.
3. Polyacryl carrier.
4. Chloroform.
5. Isopropanol.
6. 8 mM NaOH.
7. 1 M Hepes.
8. 100 mM EDTA, pH 8.0.
9. 75% ethanol.
10. 1 x PBS, pH 7.4.
11. 6-well plastic cell culture plates.
12. PBS.
13. Decorin / endorepellin.

2.8.2. Detection of mitochondrial membrane permeability via JC-1 staining
1. Attachment Factor (0.2% Gelatin in PBS)
2. 4-chamber glass slides.
3. 7.5 mM JC-1 stock solution.
4. Leica upright fluorescence microscope DM5500B.

3. Methods
3.1. Cloning of Recombinant Proteoglycans and Protein Core Fragments
To monitor matrix-induced autophagy, an optimal experimental strategy involves cloning, synthesizing,
and purifying recombinant proteoglycans and protein core fragments in the laboratory. This ensures
high purity in the process of protein preparation that is not otherwise available by purchasing
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proteoglycans from industrial resources. Here, we provide a detailed protocol of the entire process,
from cloning the recombinant proteoglycan cDNA into the expression vector to transfecting eukaryotic
HEK 293-EBNA cells with the foreign plasmid to purifying the secreted recombinant protein from cell
media. In particular, we chose the pCEP-Pu (derivative of pCEP4) expression vector containing a
BM40 secretion sequence upstream of the cDNA insertion site (54). This ensures secretion of the
recombinant proteoglycan into the media for effective purification.
1. The full cDNA coding sequence of the proteoglycan region of interest was constructed with a
preceding NheI restriction site (GCTAGC) and proceeding with nucleotides encoding for 6
histidine residues followed by the PmeI restriction site (GTTTAAACG) (see Note 7).
2. This cDNA was then cloned into pUC57 (AmpR) (see Note 8).
3. The pUC57 containing the cDNA (pUC57-cDNA) and the empty pCEP-Pu vector were
transformed into competent E. coli cells. For this purpose, 25 l competent cells were mixed
with 20 ng DNA and incubated for 30 min on ice. The solution was then incubated at 42˚C for 45
sec and put back on ice for 2 min. In each transformation, 475 l warmed LB media (no
Ampicillin added) was added and placed in a shaker at 37˚C for 1 h.
4. A portion (20 l) of each transformed solution was then aliquoted into separate tubes to make 3
dilutions in LB media (1:10, 1:100, and 1:000 with negative control). In sterile conditions, each
dilution was plated in agar plates containing 100 g/ml ampicillin and incubated at 37˚C
overnight (see Note 9).
5. Two colonies were suspended separately in 2 ml broth containing 100 g/ml ampicillin and
placed in 37˚C shaking for 6-8 h.
6. In a separate tube, 500 l of bacteria culture was suspended with 500 l glycerol stock. The
remaining 1.5 ml was spun down at 8,000 rpm for 10 min and stored at -20˚C for future plasmid
purification.
7. Plasmids from cells transformed with pUC57-cDNA and pCEP-Pu were purified from
transformed E. coli using the QIAprep Spin Miniprep kit.
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8. pUC57-cDNA and pCEP-Pu plasmid underwent double digest with NheI and PmeI. The
following was added in a PCR tube: 1 g plasmid, 5 g Cutsmart Buffer, 1 g NheI, 1 g PmeI,
and 42 g water. The solutions were subjected to the following conditions: 37˚C (2-3 h), 65˚C
(20 min), and stored at 4˚C.
9. The uncut and double digested plasmids were run on a 1% agarose gel with ethidium bromide
at 110V alongside a 1 kb ladder (see Note 10).
10. The linearized pCEP-Pu plasmid and cDNA fragment were cut out of the gel under UV light with
short blades and extracted using GeneJET gel extraction kit (Thermo Fisher) (see Note 11).
11. The DNA concentration of the extraction was measured via Nanodrop (see Note 12), and a 10:1
(vector:insert) ratio solution of 75 ng total DNA was made for ligation (see Note 13).
12. Double digested pCEP-Pu and cDNA were then ligated together. The following was added in a
PCR tube: 50 ng cDNA insert, 25 ng pCEP-Pu vector, 2 l ligase buffer, 1 l ligase, and water
up to 20 l. The reaction mixture was subjected to the following conditions: 16˚C (16 h), 65˚C
(10 min), and stored at 4˚C.
13. Ligated pCEP-Pu-cDNA were transformed into competent E. coli cells using 5 ng ligated
plasmid, selected against ampicillin, grown in culture overnight, and purified (see step 3-4) (see
Note 14).
14. Using appropriate primers (see Note 15), the cDNA was sequenced and ligated regions of the
plasmid to confirm in-frame and correct nucleotide sequence.
15. pCEP-Pu-cDNA were stably transfected into HEK 293-EBNA cells. HEK 293-EBNA cells were
grown in 10 cm dish at 37˚C in supplemented Dulbecco’s Modified Eagle Medium (DMEM) until
70-80% confluent (see Note 16). Two tubes were labeled lipofectamine and DNA and the
following were added. Lipofectamine tube: 500 l OptiMEM media, 30 l lipofectamine 2000.
DNA tube: 500 l OptiMEM media, 10 g plasmid.
16. Tubes were incubated for 5 min in room temperature.
17. Contents from the 2 tubes were mixed together and incubated for 45 min at room temperature.
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18. Media from cells were aspirated and 5 ml OptiMEM with DNA-lipofectamine mixture was added
gently to cells for 6 h at 37˚C (see Note 17).
19. OptiMEM was aspirated and replaced with 10 ml pre-warmed supplemented DMEM overnight.
20. Media was changed again with supplemented DMEM.
21. After 48 h of transfection, add supplemented DMEM with 500 ng/ml puromycin (see Note 18)
and grow in puromycin until stable colonies propagate.
22. Maintain stably transfected cell lines in supplemented DMEM with 2 g/ml puromycin.

Purification of His-tagged Recombinant Proteoglycans
23. HEK 293-EBNA cells transfected with pCEP-Pu-cDNA were propagated until 80-90% confluent
(see Note 19).
24. Media from the cells were aspirated and cells were washed with serum-free HBSS.
25. Cells were serum-starved with serum-free supplemented DMEM media with 2 g/ml puromycin
for 72 h at 37˚C (see Note 20).
26. Media was filtered in a 0.22 mM filter, and a single EDTA-free protease inhibitor mini-tablet was
dissolved in the media by rocking in room temperature (see Note 21).
27. Filtered media was transferred to a Spectra/Por 2 Dialysis membrane and concentrated with
PEG/Carbowax to ~30 ml (see Note 22).
28. Media was dialyzed in 2 L sterile water with 0.1 mM Phenylmethylsulfonyl fluoride (PMSF)
spinning at 4˚C for 36 h (see Note 23).
29. Media was dialyzed in 2 L Binding Buffer with 0.1 mM PMSF for 36 h (see Note 23).
30. An aliquot of 500 l HisPur Ni-NTA resin beads were pipetted to an open column (see Note 24).
31. An aliquot of 2 ml Equilibration Buffer then 2 ml Binding Buffer were run through the column
(see Note 25). Flow-through was discarded.
32. The dialysate was run through the column 1-3 times, and the unbound flow-through was saved.
33. An aliquot of 4 ml Binding Buffer was run through the column.
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34. An aliquot of 10 ml Elution Buffer was run through the column and 20 fractions of 500 l were
numbered and collected (see Note 26).
35. A small aliquot of 2-5 l per fraction was run on a 10% polyacrylamide gel and stained with
Coomassie dye for 20-30 min, then washed in Destain solution for 36 h.
36. Fractions containing recombinant protein were pooled together. The concentration of the
purified protein was measured by running electrophoresis with 1 and 2 l of eluted protein with
BSA standards (0.25, 0.5, 1, and 2 g) (Fig. 2).
37. Optional: To further concentrate final concentration of purified protein, PEG was used for 10-15
min.

3.2. Endothelial Cell Culture, Proteoglycan treatment, and Preparation of Lysate
1. Approximately 300 l 0.2% gelatin was incubated in 12-well plates (~4 cm2/well) in 37˚C for at
least 2 h.
2. After excess gelatin was aspirated, gelatinized 12-well plates were placed under UV light in a
laminar flow hood for 10-20 min.
3. Each well was seeded with ~5 x 104 human umbilical vein endothelial cells (HUVEC) in prewarmed supplemented VascuLife EnGS Endothelial Medium. Pre-warmed media were
replenished every 2 days until cells were grown to confluency (see Note 27).
4. After cells had been confluent for 1-2 days (see Note 28), experimental treatments were
initiated. In a sterile 15 ml tube, purified recombinant proteoglycan (200 nM) was added to cell
media (500 l/well), and the solution was incubated at 37˚C for 30 min.
5. Media from cells were aspirated, and pre-warmed proteoglycan treatments were added to wells
(500 l/well) and incubated at 37˚C for the designated time period (see Note 29).
6. Post-treatment, cell culture plates were placed on ice, and media were aspirated from wells.
Using ice-cold 1X PBS, cells were washed once, and RIPA (200 l/well) was added for 10-15
min (on ice at room temperature, rocking).
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7. Cells were manually scraped on ice. Remaining lysates from each well were vortexed in 50 l
5X Sample Buffer, boiled for 2 min, and stored in -20˚C for western blot analysis (see Note 30).

3.3 In vitro Biochemical Analysis of Matrix-Induced Autophagy
Autophagic Flux & Cell Signaling Assay
Proteoglycans such as decorin protein core and the C-terminal perlecan fragment endorepellin have
been shown to activate autophagy through inducing phosphorylation of AMPK (65,88). Further,
canonical activation of AMPK via phosphorylation at Thr172 in the T-loop region occurs
physiologically upon nutrient deprivation and inhibits mTOR activity to activate autophagy (89,90).
1. Endothelial cells were seeded and cultured appropriately (see method 3.2, steps 1-5).
2. Endothelial cells were treated with the recombinant proteoglycan ±the following signaling/flux
inhibitors: Bafilomycin A1 (500 nM) or Chloroquine (20 M), inhibits autophagosome-lysosome
fusion. Compound C (1 M), inhibits activation of AMPK. Torin 1 (20 nM), selectively inhibits
mTOR. SU5416 (30 M), VEGFR1/2 tyrosine kinase inhibitor.
3. Cells were lysed and processed for western blot analysis (see Section 3.2, steps 6-7).
4. After samples were run through an acrylamide gel and transferred onto a nitrocellulose
membrane, membranes were blocked in 1% BSA in TBST, rocking for 1 h at RT.
5. Membranes were incubated overnight in primary antibodies, diluted at 1:1000 in 1% BSA in
TBST (see Note 31) (see Table 1).
6. Once the primary antibody was removed the following day, membrane was washed three times
in TBST (15 min each).
7. Secondary antibody was added, diluted at 1:4000 for 1 h at RT and washed with TBST
thereafter for three times (15 min each).
8. Membrane was treated with chemiluminescent substrate for 2 min and visualized using an
ImageQuant machine.

3.4. Microscopic Visualization of Autophagy
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3.4.1. Electron Microscopy (EM)
1. Specimens were fixed in 2% glutaraldehyde (GA) in 0.1 M PBS at RT for 4 h.
2. After GA fixation, specimens were fixed in 1% osmium tetroxide (OT) in 0.1 M PBS at 4°C for 2
h.
3. Post-fixation tissue fragments were dehydrated in a gradient of ethanol solutions (40%, 50%,
60%, 70%, 80%, 90%, 96% and 100%).
4. Tissue fragments were embedded in plastic resin (Spurr’s solution: 33% resin, 66% resin and
100% resin) and polymerized overnight at 80°C.
5. The fix and embedded tissue fragments were cut into 0.5-1 micron thick sections using UC7
ultramicrotome with glass knife. Sections were then transferred to glass microscope slides,
stained with Toluidine Blue O stain, and observed under a light microscope to check the
morphology of the tissue.
6. After visually confirming the intactness of morphological integrity of the tissue fragment, sections
were further cut into 100-120 nm thick sections using UC7 ultramicrotome using a diamond
knife.
7. Sections were collected on copper grid and stained with uranyl acetate and lead citrate. Briefly,
a small petri was placed within a big petri making two chambers. A small petri dish was covered
with parafilm and the outer zone filled with 10-15 NaOH pellets. Big droplets of uranyl acetate
were put onto the parafilm (covering the smaller petri) with number of droplets corresponding to
number of copper grids to be stained. The copper grids were upturned with sample facing the
drops and left for 15 min to allow uptake of stain. The grids were removed, dried on paper and
sequentially washed three times in distilled water. The same process was repeated for lead
citrate in a similar but separate setup.
8. Thick sections of 100 nm were observed using a JEOL electron microscope. Digital images
were created using an Advantage HR Digital CCD camera system that was attached to the
electron microscope.
3.4.2. Atomic Force Microscopy (AFM)
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1. HUVEC were grown to confluency on attachment factor coated four-chamber slides.
2. Cells were washed with ice-cold PBS 1X and fixed in 2% glutaraldehyde diluted in HBSS.
3. Fixed cells were re-washed with PBS 1X and dried in desiccation chamber.
4. Cell structure was obtained by probing fixed cells in tapping mode using a nano-sized silicon tip
(tip radius R ~ 10 nm, spring constant ~42 N/m, NCHV-A, BrukerNano).
5. To measure the elasticity modulus of cells, they were grown up to confluency and probed
without fixing.
6. An optical microscope was used to locate individual cells before performing nano-indentation at
7 μm/s indentation depth rate using a microspherical tip (R ≈ 2.5 μm, k ≈ 0.1 N/m) in the same
media in which cells were grown (Dimension Icon AFM) (see Note 32).
7. The force-depth loading curve obtained from nano-indentation was fit using Hertz model with
the finite cell height correction, and the effective elasticity indentation modulus was calculated.
The Poisson’s ratio of the cells was set to 0.5.

3.4.3. Immunofluorescence Microscopy
1. 5 X 105 HUVEC cells were plated on attachment-factor coated 4-chamber slide and grown to
confluency.
2. The cells were washed with 1X PBS twice and fixed using 100 μl of 4% PFA per well while on
ice for 20 min.
3. The PFA was aspirated, and cells were washed again with 1X PBS (see Note 33).
4. 100 μl of the Permeabilization Buffer was added to each well and rocked for 30 s before
washing off the buffer.
5. The cells were blocked with 100 μl 1% BSA for 45 min at RT.
6. Primary antibodies were diluted at 1:200 ratio in 1% BSA solution in PBS and added 200 μl per
well for 1 h (Table 1).
7. The cells were washed thrice with 1X PBS for 5 min each.
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8. Secondary antibodies were diluted at 1:400 in 1% BSA solution in PBS and added 200 μl per
well for 1 h (Table 1).
9. The cells were then washed thrice with 1X PBS for 5 min each.
10. PBS was aspirated, and the walls of the slide were removed with a separator.
11. The slide was dried to evaporate excess PBS, and two drops mounting media containing DAPI
was added per well before overlaying slide with cover slip.
12. The corners of the slide were sealed with clear nail-polish and allowed to air dry for 2 h before
visualization.
13. The slide was viewed at 63X using Zeiss Confocal Microscope or Leica Fluorescence
Microscope.

3.6. Monitoring autophagy and angiogenesis ex vivo
3.6.1. Aortic ring assay
Aortae can be taken from wild-type C57BL/6 mice. Using a purified pro-autophagic matrix protein, aortic
rings induced with protracted autophagy showed reduced sprouting, indicative of hindered
angiogenesis, while control rings grew proficiently (Fig. 4).
3D collagen preparation for embedding aortic rings
1. The following were added to a 1.5 ml tube on ice to form the 3D collagen gel mixture: 350 μl of
collagen, 320 μl of autoclaved water, 120 μl of 199 media 10X, 280 μl of NaHCO3 and 20 μl of
NaOH (see Note 34-35).
2. Aliquots of 50 μl from the mixture were added to each well of a 96-well plate (see Note 36) and
place in a 37°C incubator for 30 min to allow polymerization of collagen gel layer 1.
3. For collagen gel layer 2, a separate 3D collagen gel mixture was made (see method 3.6.1, step
1) and kept on ice.
Dissecting and preparing aortic rings
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4. The heart and lungs of the euthanized mouse were removed to expose the aorta (see Note 37).
The aorta will appear as a fatty-white tube which runs down from the neck region to the
diaphragm along the spine.
5. Using a pair of forceps, the thoracic end of the aorta was stabilized and the abdominal end was
cut. The aorta was detached from the spine by running a scalpel gently up towards the thoracic
end of the aorta where it branches into brachiocephalic artery, left carotid and left subclavian
arteries.
6. The anterior end of the aorta was cut to release the dissected aorta (see Note 38).
7. The aorta was transferred onto a petri dish on the dissection board and immersed in HBSS.
8. Using a dissection microscope, the morphology of the aorta was verified (see Note 39). Visceral
fat was removed around the aorta using a sharp blade.
9. The aorta was cut into small, uniform rings ~0.5 mm in width.
Embedding aortic rings into collagen type I and allowing sprouting
10. Aortic rings were placed one at a time in each well of the 96-well plate layered with 3D collagen
(see method 3.6.1 step 1).
11. After placing the rings, a second layer of 50 μl collagen gel was added and incubated at 37°C
for 30 min (see method 3.6.1 step 3).
12. An aliquot of 100 μl HUVEC VascuLife EnGS endothelial medium was added to each well and
the 96-well plate was placed back into the incubator.
13. The 96-well plate was monitored every day to visualize sprouting.
14. When vessels began to sprout from the aortic rings, the purified recombinant matrix protein was
added to the surrounding media at the appropriate functional concentration (ex: 200 nM
endorepellin). As a control, an equal amount of PBS was added to the media of a separate
aortic ring.
Staining aortic rings with lectin and DAPI to visualize sprouting
15. The culture media was removed and the aortic rings were washed with HBSS.
16. Rings were fixed in 100 l of 4% PFA per well for 2 h rocking in RT.
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17. The PFA was aspirated and rings were washed with PBS (see Note 40).
18. Rings were blocked with 2% BSA in PBS for 3 h at RT (see Note 41).
19. Rings were incubated for 3 h at RT (dark) in a 1:200 dilution of lectin-1-TRITC in Blocking
Buffer to stain the endothelial cells.
20. Rings were washed 3 times in PBS for 15 min each.
21. Rings were stained with DAPI (1:1000) for 10 min (dark)
22. Rings were washed 3 times with PBS for 15 min each (see Note 42).
Visualization of the rings
23. The 96-well plate was taken to the confocal facility and visualized with 63X oil objective.
24. Zen black software was used to acquire z-stack images.
25. Image J software was used for 3D reconstruction of images acquired with Zen black. Individual
slices of z-stack were converted into a stack and then into maximum intensity projection image.

3.7. Detecting autophagy and tumor angiogenesis in vivo
3.7.1. Starvation-Induced Autophagy in GFP-LC3 Mouse Models
1. From the same cage, an equal number of GFP-LC3 mice were randomly separated into two
cages, one for each group (fed vs fasted).
2. Starting early in the morning (7-8 AM), food sources from each cage was removed for 25 h.
Water supplies were maintained to prevent dehydration.
3. Mice were immediately euthanized and dissected for biochemical and IHC analysis (see below).
Mouse Organ Dissection & Biochemistry
1. One at a time, mice were euthanized in a CO2 chamber and cervical dislocation was performed.
2. Blood was extracted as follows. The mouse abdomen, peritoneum, and chest cavity are cut
open with beating heart exposed. Using a syringe, blood was extracted from heart and
transferred to tube precoated with 0.5 M EDTA overnight. Tubes were centrifuged at 2000 rpm
for 10 min at 4˚C, and serum (supernatant) was transferred into a fresh tube using glass
pipettes.
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3. Organs were extracted (heart, lungs, kidney, liver, tumor). Organs were removed and briefly
rinsed in PBS. A small piece of each organ was cut and placed in 4% PFA for IHC. Remaining
part was placed in a 1.5 ml tube and flash frozen in liquid nitrogen and stored in -80˚C for
protein extraction (see method 3.7.3). Rock organs in PFA for 4 h at room temperature (RT).
Organs were incubated in 15% sucrose at RT, rocking for 4 h. Organs were incubated in 30%
sucrose at RT, rocking overnight.

3.7.3. Mouse Tissue Extraction for Western Blot
1. Tubes with frozen tissue were kept in liquid nitrogen throughout extraction.
2. For each tissue sample: Liquid nitrogen was poured into a mortar and pestle to pre-cool. Tissue
was crushed with pestle while submerged in liquid nitrogen (see Note 43). Remaining tissue
was stored back in -80˚C. Crushed tissue was poured into new labeled tube carefully (cover
opening of tube partially with finger to prevent tissue from coming out when liquid nitrogen
evaporated). An aliquot of 1 ml tissue extraction solution was added to tube and vortex
thoroughly. Mortar and pestle were wiped down with dry paper towel for next tissue.
3. Samples were vortexed thoroughly again (~30 sec) and centrifuged at 10,000 rpm for 8-10 min
at 4˚C.
4. Supernatant was transferred into new labeled tube, and pellet was discarded.
5. Using the Protein A280 program in the Nanodrop, protein concentration of each sample was
measured and volumes for 30 g were calculated.
6. In separately labeled tubes, 30 g of each sample was aliquoted with the appropriate amount of
5X Sample Buffer, adding water as necessary to normalize volumes.
7. Tubes were boiled for 2 min and run on a 1.5 mm 10% acrylamide gel, transferred, and probed
with the appropriate antibodies (see Note 44).
8. Remaining samples were stored at -80˚C.

3.7.3. Immunohistochemistry of Tissue Angiogenic Markers
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3.7.4.1. Mounting tissue in OCT:
1. Organs were transferred from sucrose to a dry paper towel
2. Small parts of each organ were cut and the rest put back in 4% PFA for long-term storage at
4˚C.
3. OCT was poured carefully onto labeled tissue mount (see Note 45).
4. Organs were placed in OCT, and more OCT was added to submerge organs (see Note 46).
5. Tissue blocks are placed carefully in -20°C to solidify OCT and stored at -20°C (see Note 47).

Cutting tissue sections onto slides
6. Approximately 10 glass slides were numbered and labeled per tissue mount.
7. Solidified tissue mounts were placed on dry ice for transportation to cryostat.
8. All tissue mounts were incubated in the -20°C cryostat for 5-10 min to equilibrate.
9. The plastic top of the tissue mount was removed.
10. OCT was dispensed on head of the cryostat chuck and the head of the tissue mount was
stabilized on the chuck (see Note 48).
11. Chuck was tightened onto the cryostat sectioning interface.
12. Tissue sections were cut at 8-10 m (see Note 49).
13. Slides were placed in a vacuum-tight desiccator at RT for 1 h to dry, then stored at -80°C for
future IHC.
Staining slides for IHC
14. Slides were blocked in 5% BSA in PBS for 1 h, RT (see Note 50).
15. Excess liquid was dried off the slide using a paper towel without disrupting the tissue section.
16. Tissue sections were submerged with primary antibody solution (in 5% BSA in PBS) for 1 h in
RT (see Note 51) (Table 2).
17. Slides were carefully washed 3 times in PBS.
18. Tissue sections were submerged with secondary antibody solution (in 5% BSA in PBS) for 1 h
in RT (see Note 51) (Table 2).
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19. Slides were carefully washed 3 times in PBS.
20. DAPI hard mount was applied to each section (1 drop/section), the cover slip was placed over
sections, and clear nail polish was applied to the corners. Slides were stored at 4°C in the dark.

3.8. Mitophagy Monitoring
3.8.1. Mitochondrial DNA isolation and determination
Determining mitochondrial membrane polarization (m) proceeds via live cell staining with the JC-1
vital dye. Mechanistically, JC-1 is a lipophilic cationic dye sensitive to voltage fluctuations. JC-1
accumulates in the inner mitochondrial membrane in response to m. A low m denotes loss of
membrane potential, JC-1 is monomeric and exhibits green fluorescence. However, under conditions of
health m, JC-1 accumulates proportionately to the m and forms JC-1 aggregates, shifting the JC1 emission spectrum towards a red fluorescence (91).This can be quantified using ImageJ software.
1. Sub-confluent (~75-80%) tumor cells, seeded in 6-well dishes, were treated with 200 nM
purified decorin at 37C.
2. The 6-well dish was gently placed on ice and washed once with ice-cold PBS.
3. A volume of 1 ml of RNAzol B was added to each well and pipetted up and down several times
to homogenize cells. The homogenate was transferred to a clean 2.5 ml round bottom
centrifuge tube and place on ice. The wells were washed with an additional 1 ml of RNAzol B
and transferred to the appropriate 2.5 ml tube.
4. An aliquot of 100 l chloroform for every 1 ml of RNAzol B was added and the mixture was
vortexed at maximum speed for 20 s. The tubes were incubated for 5 min at RT.
5. The tubes were centrifuged (12,000xg) for 15 minutes at RT. The RNA-containing aqueous top
layer was discarded (see Note 52).
6. An aliquot of 500 l EB for every 1 ml of RNAzol B was added to the remaining interphase and
organic phase layers. The tubes were inverted 6-7 times and incubated at RT for 10 min.
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7. The tubes were centrifuged (3000xg) for 30 min at 4C and the upper layer containing genomic
DNA and mitochondrial DNA was transferred to newly labeled 1 ml tubes.
8. An aliquot of polyacryl carrier (4 l for every 1 ml of RNAzol B used) was added followed by the
addition of isopropanol (400 l for every 1 ml of RNAzol B used) to precipitate the DNA species.
The tubes were inverted 6-7 times and incubated at RT for 10 min.
9. Tubes were centrifuged (12,000xg) for 5 min at 4C. Supernatant was discarded. The remaining
pellet was washed with 1 ml 75% ethanol and incubated at RT for 5 minutes. Tubes were
inverted 6-7 times to dislodge the pellet from the bottom of the tube and centrifuged (12,000xg)
for 5 min at 4C. The supernatant was discarded. This step was repeated four times to ensure
proper washing of the DNA pellet.
10. The pellet was air dried at RT for 5 min to remove residual ethanol (see Note 53).
11. An aliquot of 30 l 8 mM NaOH was added to dissolve the DNA pellet followed by centrifugation
(12,000xg) for 10 min at 4C to remove any undissolved material.
12. The supernatant (~30 l) was transferred to a freshly labeled 200 L tube. An aliquot of 0.5 l 1
M Hepes solution was added to bring sample pH to 8 followed by 0.5 l 100 mM EDTA. This
was vortexed for 15 s. The isolated genomic DNA/mitochondrial DNA (gDNA/mtDNA) mixture
was stored at either 4C or -20C. Repeated freeze/thaw cycles should be avoided.
13. Using 10 ng of freshly isolated DNA per reaction, conventional qPCR was conducted using the
following primer sequences (see Note 54): Primer sequences for mtDNA detection of a 0.2Kb
fragment of the ND1 gene: Forward: 5’-CCCATTCGCGTTATTCTT-3’ / Reverse: 5’AAGTTGATCGTAACGGAA-3’. Primer sequences for gDNA detection of a 0.2Kb fragment of
the

LPL

gene:

Forward:

5’-GGATGGACGGTAAGAGTGATT-3’

ATCCCAGGGTAGCAGACAGGT-3’.

3.8.2. Detection of mitochondrial membrane permeability via JC-1 staining
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/

Reverse:

5’-

1. The desired number of 4-chamber glass slides were gelatinized with 200 l 0.1% gelatin for 3 h
at 37C. Gelatin was aspirated, and plates were dried under UV-A/B for 30 min.
2. Endothelial or tumor cells were grown to confluency and treated with 200 nM decorin or 200 nM
endorepellin for desired amount of time 37C (see Note 55).
3. Cells were incubated with 7.5 M JC-1 for 20 min at 37C, then gently washed 3 times in warm
PBS. Add 500 ml of warmed cell-type appropriate media.
4. Live cells were imaged using Leica upright fluorescence microscope DM5500B.

Notes
1. Always add 1% Penicillin/Streptomycin to cell media
2. Paraformaldehyde powder is very corrosive to skin and should be handled wearing gloves, once
it’s added to warm 1X PBS it gets volatile and should be worked with a mask-on.
3. Cells should be directly transferred from the incubator to the AFM machine, not be allowed to
stand out of the incubator for more than 30 min, this compromises with their buffering ability and
induces stress in them.
4. BSA powder is temperature sensitive and should be stored at 4°C always.
5. Collagen type I rat-tail can be a little turbid but that doesn’t affect its functionality. Keep the
collagen cocktail (mixture of all the components like bases, media and collagen) on ice to avoid
rapid polymerization in the falcon tube itself. Ice helps to allow transfer of collagen gel to 96-well
plates while still in its liquid state.
6. 199 media should be phenol red-free to allow visualization of pH change (color change from
yellow to red) on addition of bases (NaOH and NaHCO3) to the collagen. Rat tail collagen I is
acidic to begin with since it has been extracted using acetic acid, adding bases allows
polymerization of the collagen into gel form. Change in pH should be visible to eliminate any
errors in collagen polymerization.
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7. Verify that cDNA sequence contains no NheI or PmeI restriction sites. Extra nucleotides may be
added to ensure that the cDNA sequence will be in-frame once inserted into the pCEP-Pu
vector.
8. Genscript offers gene synthesis of custom cDNA sequences into pUC57 (AmpR) vectors.
9. Place agar plates upside down in the incubator to prevent condensation on the agar.
10. Run the gel longer to obtain greater separation of bands.
11. Elute DNA from gel with water to obtain a lower salt solution.
12. Aim for a DNA concentration of 5-20 ng/l and ~2 260/280 ratio.
13. Calculating molar ratio of 10:1 (vector : insert) with 75 ng total DNA:
•

Ex: vector/insert = 10 kb/2 kb = 5

•

Multiplication factor to obtain 10:1 = 10/5 = 2

•

Vector = 25 ng

•

Insert = 25 x 2 = 50 ng

14. In miniprep extraction, elute with EB buffer.
15. Design sequencing primers with the following criteria:
•

Melting temperature (Tm) range of 50-65˚C

•

Cannot dimerize

•

Between 18-30 bp in length

•

GC content of 40-60%

16. Grow HEK 293-EBNA cells in culture for 2 passages before transfection.
17. Ensure that handling of lipofectamine and HEK 293-EBNA cells are entirely sterile to avoid
contamination in transfection.
18. Expect to see a lot of cell death upon puromycin addition. This ensures stable transfection.
19. Increased confluency is recommended for optimal protein secretion.
20. Cells may be serum starved for 3-5 days for optimal protein yield.
21. For long-term storage, store in -80˚C.
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22. Dialysis membrane with a lower MWCO is recommended for faster concentration (6-8 kDa
recommended).
23. Change dialysis solution once after 12-24 h for optimal dialysis.
24. Use a 1 ml pipette with the pipette tip cut slightly to prevent damaging resin beads.
25. Use glass pipettes to transfer all liquid into column to prevent protein adherence.
26. An aliquot of 500 l is approximately 10 drops.
27. Grow cells in 1 ml media per well in 12-well plate.
28. Wait at least 1 day after cells reach confluency before starting the appropriate treatment. This
allows time for cells to fully lay down their basement membrane and extracellular matrix.
29. Generally, recombinant proteoglycan treatments do not extend beyond 24 h due to protein
degradation.
30. In preparation for western blot analysis, measuring the protein concentration of each lysate is
generally not necessary since all samples came from fully confluent monolayers of endothelial
cells.
31. Membrane can also be blocked in BSA overnight and then treated with primary antibody the
following day for 3 hours, followed by washing and treating with secondary antibody for 1 h. This
step can be optimized depending on the antibody company/quality.
32. After fixing the cells, they can be stored at 4°C for 4-5 days until staining.
33. Use glass pipettes to transfer all liquid into column to prevent protein adherence.
34. It is essential that the constituents of the 3D collagen cocktail are added in the sequence
mentioned in the methods section, with bases being added at the end, to allow commencement
of polymerization after addition of all the components. Bases make the collagen (which is acidic
to begin with) into neutral constituency thus providing suitable conditions to begin
polymerization.
35. 3D collagen cocktail constituents should be thoroughly mixed to allow uniform polymerization
across the volume and homogenous texture of the gel.
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36. 96-well plate is ideal for aortic ring assay since bigger well-size plates cause diffusion of growth
factors thereby hindering sprouting.
37. Upon cutting the heart blood will spurt out of the vessels filling up the cavity. Use paper towels
to soak the blood.
38. Aorta tends to curl up when the second end is cut (anterior end). Overlay the aorta with few
drops of HBSS to smoothen out the tube, after placing it on the dissection board.
39. Esophagus of the mouse also runs close to the aorta and may be mistaken for aorta. Aorta
appears as hollow white tube with fat around it, while esophagus is pinker in appearance with
very small lumen.
40. Rings can be stored in PBS after fixing with PFA for 1 week until they are stained with
antibodies/dyes.
41. Permeabilization of aortic rings was skipped since they were only stained with lectin-1-TRITC
dye, which recognizes glycoproteins present in the basal membrane of endothelial cells. If the
rings are to be probed for any intracellular protein, they should be permeabilized with tween
which is added to PBS in which BSA is dissolved in the blocking step.
42. Rings should be visualized within 1-2 days of staining with lectin-1 and DAPI to avoid diffusion
of signal and development of contamination. For long term storage (up to 1 month), sodium
azide can be added to the wells in very low quantity.
43. Make sure to work quickly throughout and triple glove to protect hands from liquid nitrogen.
44. Avoid using mouse antibodies to probe mouse tissue to avoid nonspecific signal.
45. Avoid bubbles in OCT that interferes with cutting sections. Dispense OCT conservatively to
keep in the boundary of the tissue mount. Label tissue mount appropriately for each organ or
mouse type.
46. Keep organs in the same plane when embedding in OCT for easy sectioning.
47. For long term storage, keep tissue mounts at -80°C.
48. Let OCT cool on chuck for ~30 sec before attaching tissue mount for better adhesion.

31

49. Initially, set section thickness to 20 m until tissue in OCT is reached, then readjust to 8 m for
actual tissue section. Use brush to flatten section as it is being cut, then touch room
temperature slide to OCT section and place in slide holder in RT. Depending on the surface
area of the tissue section, two tissue sections can be placed on each slide.
50. For washing and blocking, use vertical glass chambers filled with solution that can hold multiple
slides for better efficiency.
51. For neater immunostaining, use a wax pencil to draw a circular boundary around the tissue
section on the slide.
52. Instead of discarding the aqueous RNA phase, RNA can be isolated from this phase to verify
target RNA levels. For example, if a protein has been implicated in mitophagy, one can
knockdown the target protein via RNAi techniques and verify depletion via the target RNA in the
same samples being assayed for mtDNA content.
53. An alternative to air drying for 5 minutes, a KimWipe (or sterile Q-tip) can be used to remove the
residual ethanol. Great care must be taken to avoid adsorption of the pellet to the KimWipe or
Q-tip.
54. Primer stock concentration are at 100 M and utilized at a working concentration of 10 M.
Calculate fold changes according to the comparative CT method using the gDNA CT values as
calibrator samples. As an alternative to mtDNA quantification via the comparative CT method,
establishing a standard curve of known gDNA concentrations can be used to calculate absolute
copy numbers of the mtDNA per condition.
55. It is strongly encouraged to run a positive control for the JC-1 staining. Known protonophores
such

as

carbonyl

cyanide-m-chlorophenylhydrazine

(CCCP)

or

carbonyl

cyanide-p-

trifluoromethoxy-phenylhydrazone (FCCP). It is recommended to use CCCP at 30 M and
FCCP at 500 nM for either 1 h or 15 minutes, respectively.
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Fig. 1. Working model depicting the mechanism of action of endorepellin and Torin 1 (both red).
Endorepellin is an angiostatic and pro-autophagic factor. Torin 1 is a pro-autophagic factor.
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Fig. 2. Example of purified recombinant endorepellin run alongside a BSA concentration curve. The
10% acrylamide gel was run at 18 mA, stained with Coomassie Brilliant Blue dye for 30 min, and
destained for 36 h. The calculated concentration of this endorepellin purification is 0.25 mg/ml.
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Fig. 3. Visualizing matrix-induced autophagosomes in vitro. Representative immunofluorescence
images of HUVEC treated with vehicle (A), endorepellin (200 nM, 4 h) (B), and serum-starved (HBSS, 4
h) (C). Cells were dually stained with antibodies against Beclin 1 (red) and LC3 (green), with prominent
autophagosomes showing colocalization (yellow, arrows). Scale bar = 10 m.
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Fig. 4. Confocal microscopy depicting the difference in microvessel growth between vehicle (PBS) and
recombinant endorepellin-treated rings. (A) Dense, long sprouts (yellow arrows) emanating from control
aortic rings treated with Vehicle (PBS). Rings were stained with CD31 (red). (B). Collapsed
microvessels in aortic rings treated with endorepellin (200 nM). Rings were stained with CD31 (red).
Scale bar = 300 m.
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Fig. 5. LC3 puncta formation in heart tissue of fasted GFP-LC3 transgenic mice ablated in GFPLC3;Dcn-/- mice. (A-D) Representative immunohistochemistry images of heart sections from GFP-LC3
mice that were fed (A) or fasted for 25 h (B), showing increased LC3 puncta in fasted hearts. Heart
sections from GFP-LC3;Dcn-/- that were fed (C) or fasted for 25 h (D) did not show this increase in
puncta formation.
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Fig. 6. Visualizing mitochondrial depolarization via JC-1 staining. (A-D) Representative fluorescence
micrographs depicting live cell imaging of HUVEC after incubation with vehicle (A), endorepellin (6 h)
(B), CCCP (1 h, 30 M) (C), or FCCP (10 min, 500 nM) (D). HUVEC were cultured in nutrient-rich
media and incubated with JC-1 (20 min, 7.5 M) to assess mitochondrial membrane potential. Scale
bar ~50 m.
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Table 1
Antibodies for Western Blot Analysis
Primary antibody

IHC Dilution

Anti-LC3B

1:1000

Source
organism
Rabbit

Anti-p62/SQSTM1

1:1000

Anti-ATG9A

Company

Marker

Sigma

Autophagosome

Rabbit

Abcam

Autophagosome

1:1000

Rabbit

Abcam

Trans-Golgi Network &
Endosome/Autophagosome

Anti-GAPDH

1:10000

Rabbit

Cell Signaling

Loading control

Anti-PINK1

1:1000

Rabbit

Cell Signaling

Anti-ANT

1:1000

Rabbit

Cell Signaling

Anti-VDAC1

1:1000

Rabbit

Cell Signaling

Anti-Hsp60

1:1000

Rabbit

Cell Signaling

Anti-Mitofusin 2

1:1000

Mouse

Abcam

Total OxPhos
Human Antibody
Cocktail

1:1000

Mouse

Abcam

Secondary antibody
Alexa Fluor 488 anti-rabbit
IgG
Alexa Fluor 594 anti-rabbit
IgG
Alexa Fluor 594 anti-mouse
IgG

Outer mitochondrial
membrane
Outer mitochondrial
membrane
Outer mitochondrial
membrane
Mitochondrial matrix
Outer mitochondrial
membrane & Endoplasmic
Reticulum
Mitochondrial Matrix &
Inner mitochondrial
membrane

IHC Dilution

Source organism

Company

1:400

Goat

Thermo Fisher

1:400

Donkey

Thermo Fisher

1:400

Rabbit

Thermo Fisher
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Table 2
Antibodies for Tissue Immunohistochemistry
Primary antibody

IHC Dilution

Anti-CD31

1:50

Source
organism
Rabbit

Anti-LYVE1

1:200

HA binding protein,
biotinylated

Company

Marker

Abcam

Endothelial vessels

Rabbit

Abcam

Lymphatics

5 g/ml

Bovine nasal
cartilage

Calbiochem

Hyaluronan

Isolectin GS-IB4
AF594 conjugate

1:300

Griffonia
simplicifolia

Thermo Fisher

Endothelial vessels

Anti-His6

1:200

Mouse

Anti-LC3B

1:200

Rabbit

BD
Pharmingen
Sigma

His6-tagged protein
Autophagosome

Secondary antibody
Alexa Fluor 594 anti-rabbit
IgG

IHC Dilution

Source organism

Company

1:400

Goat

Thermo Fisher

Streptavidin Alexa Fluor 594

1:400

—

Thermo Fisher

Alexa Fluor 594 anti-mouse
IgG

1:400

Rabbit

Thermo Fisher
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